Debrisoquine metabolism and genetic predisposition to lung cancer.
作者信息
Law M R, Hetzel M R, Idel J R
机构信息
Department of Environmental and Preventive Medicine, St Bartholomew's Hospital Medical College, Charterhouse Square, London, UK.
出版信息
Br J Cancer. 1989 May;59(5):686-7. doi: 10.1038/bjc.1989.142.
Abstract
摘要
相似文献
1
Debrisoquine metabolism and genetic predisposition to lung cancer.异喹胍代谢与肺癌的遗传易感性
Br J Cancer. 1989 May;59(5):686-7. doi: 10.1038/bjc.1989.142.
2
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Genet Epidemiol. 1989;6(4):517-24. doi: 10.1002/gepi.1370060406.
3
Debrisoquine oxidation phenotype and susceptibility to lung cancer.异喹胍氧化表型与肺癌易感性
Br J Clin Pharmacol. 1990 Jan;29(1):101-9. doi: 10.1111/j.1365-2125.1990.tb03608.x.
4
Lung cancer and the debrisoquine metabolic phenotype.
J Natl Cancer Inst. 1990 Aug 1;82(15):1264-72. doi: 10.1093/jnci/82.15.1264.
5
Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
Cancer Res. 1989 Jul 1;49(13):3675-9.
6
[Research on the genetic polymorphism of hydroxy metabolism of debrisoquine and its significance].
Sheng Li Ke Xue Jin Zhan. 1988 Apr;19(2):130-4.
7
Debrisoquine oxidation phenotype and susceptibility to lung cancer.异喹胍氧化表型与肺癌易感性
Br J Clin Pharmacol. 1990 Oct;30(4):653-6. doi: 10.1111/j.1365-2125.1990.tb03832.x.
8
The metabolism of [14C]-debrisoquine in man.人体中[14C]-异喹胍的代谢
Br J Clin Pharmacol. 1979 Mar;7(3):257-66. doi: 10.1111/j.1365-2125.1979.tb00930.x.
9
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Clin Pharmacol Ther. 1984 Oct;36(4):515-9. doi: 10.1038/clpt.1984.212.
10
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化：相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
引用本文的文献
1
Adolescent medical providers' willingness to recommend genetic susceptibility testing for nicotine addiction and lung cancer risk to adolescents.青少年医疗服务提供者是否愿意向青少年推荐用于尼古丁成瘾和肺癌风险的遗传易感性检测。
J Pediatr Psychol. 2009 Jul;34(6):617-26. doi: 10.1093/jpepsy/jsn086. Epub 2008 Aug 7.
2
Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer.细胞色素P-450（1A1、2D6和2E1）基因多态性与胰腺癌易感性之间的关联。
Korean J Intern Med. 1997 Jun;12(2):128-36. doi: 10.3904/kjim.1997.12.2.128.
3
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Eur J Clin Pharmacol. 1997;51(5):389-93. doi: 10.1007/s002280050219.
4
Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism.细胞色素P450 IID的分子遗传学。药物代谢异常。
Clin Rev Allergy Immunol. 1995 Fall;13(3):211-21. doi: 10.1007/BF02771762.
5
The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990).癌症风险流行病学研究中病例对照方法的基本原理（对斯皮尔斯等人1990年文章的回应）
Br J Clin Pharmacol. 1990 Jul;30(1):149-50. doi: 10.1111/j.1365-2125.1990.tb03756.x.
6
Debrisoquine oxidation phenotype and susceptibility to lung cancer.异喹胍氧化表型与肺癌易感性
Br J Clin Pharmacol. 1990 Oct;30(4):653-6. doi: 10.1111/j.1365-2125.1990.tb03832.x.
7
Genetic predisposition to lung cancer.肺癌的遗传易感性。
Br J Cancer. 1990 Feb;61(2):195-206. doi: 10.1038/bjc.1990.37.
8
Ha-ras-1 alleles in Norwegian lung cancer patients.
Hum Genet. 1990 Nov;86(1):40-4. doi: 10.1007/BF00205169.
9
N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.吉尔伯特综合征患者的N-乙酰化和异喹胍羟基化多态性
Br J Clin Pharmacol. 1991 Oct;32(4):467-72. doi: 10.1111/j.1365-2125.1991.tb03932.x.
10
Polymorphisms in oxidative drug metabolism: relationship to food preference.氧化药物代谢中的多态性：与食物偏好的关系。
Br J Clin Pharmacol. 1991 Aug;32(2):235-7. doi: 10.1111/j.1365-2125.1991.tb03887.x.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
Clinical pharmacology. Possible clinical importance of genetic differences in drug metabolism.临床药理学。药物代谢中基因差异可能具有的临床重要性。
Br Med J (Clin Res Ed). 1981 Aug 22;283(6290):537-42. doi: 10.1136/bmj.283.6290.537.
3
Polymorphic drug oxidation in humans.人类的多态性药物氧化
Fed Proc. 1984 May 15;43(8):2298-302.
4
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.代谢氧化表型作为肺癌易感性的标志物。
Nature. 1984;312(5990):169-70. doi: 10.1038/312169a0.
5
Impairement of drug metabolism in tumor-bearing animals.
Eur J Cancer (1965). 1971 Dec;7(6):565-77. doi: 10.1016/0014-2964(71)90064-8.
6
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.一项关于决定异喹胍多态性羟化的遗传和环境因素的家族研究。
Clin Pharmacol Ther. 1985 Oct;38(4):394-401. doi: 10.1038/clpt.1985.193.
7
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.异喹胍代谢缺陷人类常见遗传缺陷的特征分析。
Nature. 1988 Feb 4;331(6155):442-6. doi: 10.1038/331442a0.
8
The metabolism of [14C]-debrisoquine in man.人体中[14C]-异喹胍的代谢
Br J Clin Pharmacol. 1979 Mar;7(3):257-66. doi: 10.1111/j.1365-2125.1979.tb00930.x.
9
Polymorphism of carbon oxidation of drugs and clinical implications.药物碳氧化的多态性及其临床意义。
Br Med J. 1978 Sep 2;2(6138):655-7. doi: 10.1136/bmj.2.6138.655.
Zotero 插件